Sejong Medical Co., Ltd.

KOSDAQ:A258830 Stock Report

Market Cap: ₩23.0b

Sejong Medical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sejong Medical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth35.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Sejong Medical (KOSDAQ:258830) Might Be Having Difficulty Using Its Capital Effectively

Mar 24
Sejong Medical (KOSDAQ:258830) Might Be Having Difficulty Using Its Capital Effectively

Update: Sejong Medical (KOSDAQ:258830) Stock Gained 53% In The Last Year

Mar 02
Update: Sejong Medical (KOSDAQ:258830) Stock Gained 53% In The Last Year

Does The Market Have A Low Tolerance For Sejong Medical Co., Ltd.'s (KOSDAQ:258830) Mixed Fundamentals?

Feb 11
Does The Market Have A Low Tolerance For Sejong Medical Co., Ltd.'s (KOSDAQ:258830) Mixed Fundamentals?

We're Not Counting On Sejong Medical (KOSDAQ:258830) To Sustain Its Statutory Profitability

Jan 27
We're Not Counting On Sejong Medical (KOSDAQ:258830) To Sustain Its Statutory Profitability

Is Sejong Medical Co., Ltd. (KOSDAQ:258830) A Smart Choice For Dividend Investors?

Jan 12
Is Sejong Medical Co., Ltd. (KOSDAQ:258830) A Smart Choice For Dividend Investors?

Income Investors Should Know That Sejong Medical Co., Ltd. (KOSDAQ:258830) Goes Ex-Dividend Soon

Dec 25
Income Investors Should Know That Sejong Medical Co., Ltd. (KOSDAQ:258830) Goes Ex-Dividend Soon

Should We Be Excited About The Trends Of Returns At Sejong Medical (KOSDAQ:258830)?

Dec 23
Should We Be Excited About The Trends Of Returns At Sejong Medical (KOSDAQ:258830)?

These 4 Measures Indicate That Sejong Medical (KOSDAQ:258830) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Sejong Medical (KOSDAQ:258830) Is Using Debt Reasonably Well

The Sejong Medical (KOSDAQ:258830) Share Price Has Gained 42% And Shareholders Are Hoping For More

Nov 19
The Sejong Medical (KOSDAQ:258830) Share Price Has Gained 42% And Shareholders Are Hoping For More

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sejong Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A258830 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/202419,101-71,605-1,5671,511N/A
12/31/202317,992-23,0876612,763N/A
12/31/202216,083-91,366-1,332-429N/A
9/30/202216,931-5,411-14,459-9,778N/A
6/30/202213,361-5,375-14,137-9,540N/A
3/31/202217,759-6,111-14,040-9,376N/A
12/31/202118,021-5,192-12,999-8,349N/A
9/30/202117,703-1,762-901,195N/A
6/30/202117,079-985-474675N/A
3/31/202115,881-64441,096N/A
12/31/202015,098470-1,365191N/A
9/30/202015,4651,682-4,0061,587N/A
6/30/202015,2382,668-2,8013,662N/A
3/31/202015,8293,173-4,1674,034N/A
12/31/201916,2303,464-3,8504,480N/A
9/30/201915,9243,636234,786N/A
6/30/201915,9273,9423694,624N/A
3/31/201915,3093,6956483,235N/A
12/31/201814,8333,787-921,840N/A
9/30/201813,6222,3151,7642,668N/A
6/30/201814,1022,5161,4901,981N/A
3/31/201814,4733,1672,4693,058N/A
12/31/201714,5503,214N/A4,324N/A
12/31/201612,7733,169N/A3,925N/A
12/31/201511,9571,550N/A3,306N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A258830's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if A258830's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A258830's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A258830's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A258830's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if A258830's Return on Equity is forecast to be high in 3 years time


Discover growth companies